Stem cell therapy ‘cures’ first woman with HIV, say researchers
gene editing, HIV, infectious disease, stem cell therapy
0 Comment
gene editing
Bayer trumpets $1bn CRISPR deal with Mammoth Bio
Bayer, CRISPR, gene editing, hepatology, Mammoth Biosciences, partnering
0 Comment
Vertex builds in gene editing yet again, with $1.2bn Arbor deal
Arbor Biotechnologies, beta thalassaemia, CRISPR/Cas9, gene editing, sickle cell disease, type 1 diabetes, Vertex Pharma
0 Comment
Intellia, Regeneron ace first trial with ‘in vivo’ CRISPR drug
ATTR amyloidosis, CRISPR/Cas9, gene editing, Intellia Therapeutics, rare disease, Regeneron
0 Comment
Nobel winner Charpentier’s CRISPR Therapeutics gets $900m in reworked Vertex deal
CRISPR, CRISPR Therapeutics, Editas, gene editing, Vertex
0 Comment
Vertex eyes controllable genetic drugs with $1.3bn Obsidian alliance
CRISPR Therapeutics, CRISPR/Cas9, gene editing, Obsidian Therapeutics, partnering, Vertex Pharma
0 Comment
Casting aside CRISPR scissors and making a point with base editors
CRISPR, gene editing, immune cell therapy, Kymriah, Perkin Elmer, Yescarta
0 Comment
Gene editing: beyond the hype
CAR, CAR-Tregs, cell and gene therapy, cell therapy, CRISPR, gene editing, gene therapy, JP Morgan, Sangamo
0 Comment
